General MedicationsINJECTIONStandard
PRAXBIND
IDARUCIZUMAB
Standard Dose
2.5G/50ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview PRAXBIND is listed in Drugs@FDA under application 761025 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient IDARUCIZUMAB Form and strength INJECTABLE;INJECTION - 2.5G/50ML Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2022-02-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview PRAXBIND is listed in Drugs@FDA under application 761025 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient IDARUCIZUMAB Form and strength INJECTABLE;INJECTION - 2.5G/50ML Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2022-02-11 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.